EP131 - Diagnostic Value of the MaRIA Index and Its Correlation with Clinical and Biochemical Parameters in Patients with Crohn’s Disease.

ePoster Presenter(s)

• VS

  Valeria Sebastian, MD

  General Practicioner
  IBD Clinic. Coloproctology Service. Hospital General de Mexico "Dr. Eduardo Liceaga"
  CDMX, Distrito Federal, Mexico

  Disclosure information not submitted.

Author(s)

• EC

  Estefania Contreras Aviles, Medical Student

  Medical Student
  Hospital General de México “Dr. Eduardo Liceaga”. Inflammatory Bowel Disease Clinic. Coloproctology Service.
  Ciudad de Mexico, Distrito Federal, Mexico

  Disclosure information not submitted.
• PR

  Paola Rosales Téllez, MD

  Surgeon
  Coloproctology service, Hospital General de México
  Hospital General de México
  Mexico City, Distrito Federal, Mexico

  Disclosure information not submitted.
• EG

  Emmanuel González, MD

  General Surgeon
  Coloproctology Service. Hospital General de México "Dr Eduardo Liceaga"
  CDMX, Distrito Federal, Mexico

  Disclosure information not submitted.
• JC

  Jesus Chida, MD

  Gastroentherologyst
  IBD Clinic. Coloproctology Service. Hospital General de Mexico "Dr. Eduardo Liceaga"
  CDMX, Distrito Federal, Mexico

  Disclosure information not submitted.
• VH

  Victor Hernández, MD

  General Practicioner
  IBD Clinic. Coloproctology Service. Hospital General de Mexico "Dr. Eduardo Liceaga"
  CDMX, Distrito Federal, Mexico

  Disclosure information not submitted.
• HR

  Hector Rodríguez, MD

  General Practicioner
  IBD Clinic. Coloproctology Service. Hospital General de Mexico "Dr. Eduardo Liceaga"
  CDMX, Distrito Federal, Mexico

  Disclosure information not submitted.
• RL

  Raquel Y. López, MD

  Gastroentherologyst and Gastrointestinal Endoscopist.
  IBD Clinic. Coloproctology Service. Hospital General de Mexico "Dr. Eduardo Liceaga"
  CDMX, Distrito Federal, Mexico

  Disclosure information not submitted.
• BJ

  Billy Jimenez Bobadilla, n/a

  Doctor
  Hospital General de Mexico
  Ciudad de Mexico, Distrito Federal, Mexico

  Disclosure information not submitted.

Senior Author(s)

• 

  Jorge Luis De Leon Rendon, 7948396 (he/him/his)

  Coordinator and Founder, Inflammatory Bowel Disease Clinic
  Hospital General de México “Dr. Eduardo Liceaga”. Inflammatory Bowel Disease Clinic. Coloproctology Service.
  CDMX, Distrito Federal, Mexico

  All of the relevant financial relationships listed below have been mitigated.
  This individual has no relevant relationships with ineligible companies.

Purpose/Background: Introduction.

Crohn's disease (CD) is a chronic, transmural inflammatory disorder that may

lead to stenosis, fistulas, and abscesses. Ileocolonoscopy is the gold standard for mucosal

assessment, but its repeated use is limited by its invasive nature. Magnetic Resonance

Index of Activity (MaRIA) provides a non-invasive evaluation of inflammatory activity.

Correlating MaRIA with clinical indices and biomarkers may optimize disease monitoring,

particularly in resource-limited settings.

Aim.

To determine the correlation between MaRIA index and clinical/biochemical

parameters-Harvey-Bradshaw Index (HBI), Crohn's Disease Activity Index (CDAI),

C-reactive protein (CRP), and fecal calprotectin (FC)-in patients with CD at a tertiary care

center in Mexico.

Methods/Interventions: A retrospective, observational, analytical study was conducted in 46 patients with

CD treated at the Inflammatory Bowel Disease Clinic of the Hospital General de México.

Data collected included enterography findings (MaRIA index), clinical indices, and

biomarkers. Distribution was assessed using the Shapiro-Wilk test; correlations were

evaluated using Spearman's rank test. ROC curves were constructed to assess the

discriminative ability of MaRIA for clinical remission. Analyses were performed with SPSS

v29.

Results/Outcomes: Clinical and demographic characteristics are summarized in Table 1. The mean

age was 47.5 years, and 58.7% were women. According to the Montreal classification, L3

location predominated (41.3%), and A2-A3 age groups were most frequent (47.8%).

Extraintestinal manifestations were observed in 47.8%, and perianal disease in 28.3%.

Biologic therapy was used by 78.3%, predominantly ustekinumab (52.2%). During follow-up,

45.7% were hospitalized and 41.3% required surgery. MaRIA showed a significant positive

correlation with HBI (rho = 0.525, p = 0.0021) and CDAI (rho = 0.522, p = 0.0022), but no

association with CRP (rho = 0.293, p = 0.1037) or FC (rho = 0.053, p = 0.7721). ROC

analysis showed an AUC of 0.750 for HBI and 0.821 for CDAI, indicating good discriminative

ability for identifying clinical activity.

Conclusion/Discussion: The MaRIA index demonstrated significant correlation with clinical indices (HBI

and CDAI) but not with biochemical biomarkers. These findings suggest that MaRIA may

represent a reliable, non-invasive tool for assessing inflammatory activity in CD, particularly

valuable in settings with limited resources.

Table 1. Clinical and Demographic characteristics of patients with Crohn's Disease
*Montreal Classification (CD): A = Age at diagnosis; L = Disease location; B = Disease behavior; P = Perianal disease.